MarketCap
Facebook
X
TelegramAnnual report 2024
added 12-27-2025
OrganiGram Holdings Revenue 2011-2026 | OGI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue OrganiGram Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 160 M | 162 M | 146 M | 79.2 M | 86.8 M | 80.4 M | 12.4 M | 5.71 M | 6.13 M | 81.1 K | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 162 M | 81.1 K | 73.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
651 K | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.11 | 4.39 % | $ 119 M |  Canada |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.67 | 2.5 % | $ 1.38 B | Canada |
 |
Evolus
EOLS
|
297 M | $ 5.09 | 23.24 % | $ 328 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
702 K | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
4.53 M | $ 0.58 | 2.89 % | $ 10.1 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 4.24 | -7.42 % | $ 59.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
25 M | - | - | $ 193 M | Canada |
 |
Harrow Health
HROW
|
272 M | $ 39.82 | 3.15 % | $ 1.46 B | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.67 | 5.32 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 8.81 | -1.12 % | $ 451 M | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
152 M | $ 12.16 | 2.23 % | $ 864 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 5.6 | -2.19 % | $ 2.04 B | Canada |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 2.98 | 3.66 % | $ 392 M | USA |
 |
Rockwell Medical
RMTI
|
83.6 M | $ 0.9 | -0.21 % | $ 21 M | USA |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 11.58 | 1.71 % | $ 1.6 B | USA |
 |
Sundial Growers
SNDL
|
920 M | $ 1.56 | 1.63 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
1.3 M | $ 2.24 | 0.94 % | $ 23.4 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.63 | 4.37 % | $ 355 M | USA |
 |
Viatris
VTRS
|
15.4 B | $ 14.79 | -0.71 % | $ 17.8 B | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 22.67 | 2.58 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.81 | 3.0 % | $ 145 M | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.82 | 4.7 % | $ 3.54 M | USA |
 |
SCYNEXIS
SCYX
|
140 M | $ 0.76 | 1.09 % | $ 36.4 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 2.77 | 0.65 % | $ 3.44 M | USA |
 |
Tilray
TLRY
|
627 M | $ 7.55 | 2.51 % | $ 4.67 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |